Cannabis company Canopy Growth stock drops after $30 million private placement at a discount price
By Steve Gelsi
Constellation-backed marijuana company continues its moves to strengthen its balance sheet
Canopy Growth Corp.'s stock was down 9.5% to $4.56 a share on Tuesday after the company said it agreed to sell $30 million in units in a private placement with institutional investors.
While it's backed by deep-pocketed liquor giant Constellation Brands Inc., (STZ), Canopy Growth (CGC) (CA:WEED) has yet to turn a profit and it's been making moves to strengthen its balance sheet.
Also read: Once-mighty Canopy Growth loses billions as dream of pot riches runs into reality of oversupply and overspending
Canopy Growth said it OK'd the sale at a price of $4.29 per unit, which is below the stock's closing price of $5.04 a share on Monday.
Canopy Growth will use the proceeds to reduce its debt.
Each unit will be made up of one common share of the company and one warrant, which will entitle holders to buy one common share at $4.83 a share.
Canopy Growth's stock is down 81% in the past year, compared to a drop of 23.6% for its rival in Canada, Tilray Brands Inc.(TLRY) (CA:TLRY).
Also read: Canopy Growth's cash burn raises analyst concerns
-Steve Gelsi
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
01-09-24 1217ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth